Blood cancers, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Results
Phase 2
This study looked at rituximab, cyclophosphamide and bortezomib for Waldenstrom’s macroglobulinaemia. This is pronounced wall-den-stroms mak-row-glob-you-lin-ee-mee-a
Waldenstrom’s macroglobulinaemia (WM) is a rare type of lymphoma called lymphoplasmacytic lymphoma (LPL). It is a slow growing type of non-Hodgkin lymphoma (NHL).
This study was supported by Cancer Research UK. It was open for people to join between 2013 and 2015. The team published the results in 2024.
Recruitment start: 18 January 2013
Recruitment end: 20 September 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Rebecca Auer
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Janssen-Cilag
NIHR Clinical Research Network: Cancer
Roche
University College London (UCL)
This is Cancer Research UK trial number CRUK/11/030.
Last reviewed: 04 Sept 2025
CRUK internal database number: 8777
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
